Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia.
DYSF gene
LGMD2B
Miyoshi myopathy
Saudi Arabia
dysferlin
dysferlinopathy
limb-girdle muscular dystrophies (LGMD)
neurophysiological profile
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
11
2021
accepted:
31
01
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
Sections du résumé
Background
UNASSIGNED
To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy.
Methods
UNASSIGNED
A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info.
Results
UNASSIGNED
33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families.
Conclusion
UNASSIGNED
The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
Identifiants
pubmed: 35273475
doi: 10.3389/fnins.2022.815556
pmc: PMC8902167
doi:
Types de publication
Journal Article
Langues
eng
Pagination
815556Informations de copyright
Copyright © 2022 Alharbi, Matar, Cupler, Al-Hindi, Murad, Alhomud, Monies, Alshehri, Alyahya, Meyer and Bohlega.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Brain. 2009 Nov;132(Pt 11):3175-86
pubmed: 19767415
Hum Mutat. 2005 Aug;26(2):165
pubmed: 16010686
Intern Med. 2010;49(24):2693-6
pubmed: 21173544
Neuromuscul Disord. 2018 Aug;28(8):702-710
pubmed: 30055862
Neurology. 2010 Jul 27;75(4):316-23
pubmed: 20574037
Neuromuscul Disord. 2003 Sep;13(7-8):532-44
pubmed: 12921790
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1071-1081
pubmed: 29735511
Neuromuscul Disord. 1995 Jan;5(1):71-4
pubmed: 7719146
Acta Neurol Scand. 2009 Aug;120(2):111-8
pubmed: 19154541
Neurol India. 2008 Jul-Sep;56(3):289-97
pubmed: 18974555
Acta Myol. 2011 Dec;30(3):185-7
pubmed: 22616201
Neuromuscul Disord. 2008 Jan;18(1):34-44
pubmed: 17897828
Genome Biol. 2015 Jun 26;16:134
pubmed: 26112015
Ann Neurol. 1997 Aug;42(2):222-9
pubmed: 9266733
J Neurol Sci. 2003 Jul 15;211(1-2):23-8
pubmed: 12767493
Pediatr Rheumatol Online J. 2013 May 03;11(1):19
pubmed: 23641709
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018 Aug 10;35(4):498-501
pubmed: 30098242
Neuromuscul Disord. 2006 Mar;16(3):208-9
pubmed: 16483775
PLoS Curr. 2015 Oct 29;7:
pubmed: 26579332
Neurology. 2003 Jun 10;60(11):1799-804
pubmed: 12796534
Isr Med Assoc J. 2006 Feb;8(2):110-3
pubmed: 16544734
Neurology. 2001 Jul 24;57(2):271-8
pubmed: 11468312
Hum Mol Genet. 1994 Mar;3(3):455-7
pubmed: 8012357
Dtsch Med Wochenschr. 1965 Nov 5;90(45):2002-7
pubmed: 5319468
J Clin Rheumatol. 2014 Aug;20(5):275-7
pubmed: 25036559
Neuromuscul Disord. 1995 Jul;5(4):337-43
pubmed: 7580247
Clin Rheumatol. 2010 Jan;29(1):103-6
pubmed: 19730931
Neuromuscul Disord. 2014 Jun;24(6):482-91
pubmed: 24780148
Brain. 2000 Jun;123 ( Pt 6):1229-37
pubmed: 10825360
Hum Mutat. 2008 Feb;29(2):258-66
pubmed: 17994539
Neuromuscul Disord. 2007 Feb;17(2):157-62
pubmed: 17129727
Muscle Nerve. 2012 Mar;45(3):338-45
pubmed: 22334167
J Neurol Sci. 2001 Feb 15;184(1):15-9
pubmed: 11231027
Am J Pathol. 2014 Jun;184(6):1668-76
pubmed: 24685690
Orphanet J Rare Dis. 2013 Feb 14;8:26
pubmed: 23406536
Arq Neuropsiquiatr. 2008 Mar;66(1):80-2
pubmed: 18392421
Neuromuscul Disord. 2007 Dec;17(11-12):950-4
pubmed: 17825554
Muscle Nerve. 2018 Aug;58(2):167-177
pubmed: 29350766
Brain. 1997 Nov;120 ( Pt 11):1989-96
pubmed: 9397016
J Neuropathol Exp Neurol. 2006 Oct;65(10):995-1003
pubmed: 17021404
Med Klin (Munich). 2004 Jun 15;99(6):326-9
pubmed: 15221058
Mol Med Rep. 2014 May;9(5):1515-32
pubmed: 24626787
Neuromuscul Disord. 2003 Dec;13(10):788-95
pubmed: 14678801
Hum Mol Genet. 1999 May;8(5):855-61
pubmed: 10196375
Muscle Nerve. 2016 Mar;53(3):394-401
pubmed: 26088049
Neurology. 2009 Apr 21;72(16):1432-5
pubmed: 19380703
Hum Mol Genet. 1999 May;8(5):871-7
pubmed: 10196377
Neuromuscul Disord. 1998 Jun;8(5):321-6
pubmed: 9673986
Mov Disord. 2006 Sep;21(9):1513-5
pubmed: 16817213
Nature. 2003 May 8;423(6936):168-72
pubmed: 12736685
Arch Neurol. 2007 Aug;64(8):1176-82
pubmed: 17698709
Arch Neurol. 2005 Aug;62(8):1256-9
pubmed: 16087766
Curr Opin Neurol. 2016 Oct;29(5):635-41
pubmed: 27490667
Ann Neurol. 2001 Jan;49(1):130-4
pubmed: 11198284
Am J Med Genet. 2000 Apr 10;91(4):305-12
pubmed: 10766988
Neurol India. 2014 Nov-Dec;62(6):635-9
pubmed: 25591676
Nat Genet. 1998 Sep;20(1):31-6
pubmed: 9731526
Neurology. 1998 Jan;50(1):41-6
pubmed: 9443455
Acta Myol. 2015 Dec;34(2-3):95-108
pubmed: 27199536
Eur Rev Med Pharmacol Sci. 2021 Aug;25(15):4941-4952
pubmed: 34355366
Brain. 1986 Feb;109 ( Pt 1):31-54
pubmed: 3942856
Neurology. 2007 Jun 12;68(24):2125-8
pubmed: 17562833
Dis Markers. 2015;2015:543282
pubmed: 26063958
Ann Neurol. 2006 May;59(5):808-15
pubmed: 16634037
BMC Neurol. 2015 Oct 06;15:182
pubmed: 26444858
Skelet Muscle. 2011 Mar 01;1(1):10
pubmed: 21798087
Neurogenetics. 2010 Oct;11(4):449-55
pubmed: 20623375